icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
TLR7 Agonist GS-9620 (Vesatolimod) Increases Immune-Mediated
Clearance of HIV-Infected Cells
  Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
At CROI 2017 there were 3 studies - this oral on TLR7, and 2 posters on a TLR7 and TLR 9 agonists. Here is below slide presentation on TLR7 & link to webcast, following immediately are my email reports of the 2 poster presentations.
from Jules: the promise of LRAs (latency reversal agents) and HDACsi in HIV cure research is at this point disappointing to some researchers in the field and so hope and the current attention in research includes TLR agonists including TLR7 and TLR9, 2 recently announced studies reflect that -
........http://www.natap.org/2017/HIV/012317_06.htm.......a recent cure research study was announced New HIV Eradication Combo Study "a novel "kick-and-kill" concept of HIV eradication" - (01/13/17) that will study this TLR9 agonist with 2 neutralizing antibodies. .....Reported at CROi 2016 Gilead's TLR7 in monkeys induced immune cytokine response, reduced DNA levels, and after stopping ART 2 of the 9 monkeys had undetectable plasma HIV http://www.natap.org/2016/CROI/croi_22.htm..
(study 1) announced "a planned clinical study in HIV-positive patients on antiretroviral therapy (ART) evaluating MOLOGEN's TLR9 agonist, the Immune Surveillance Reactivator (ISR) lefitolimod in combination with novel virus-neutralizing antibodies developed by Rockefeller University" - and - (study 2) a 2nd study announced in Nov 2016 by Janssen - "The objective of our study was to identify a functional cure for HIV - not to eradicate the virus, but to control it without the need for ART"....."Phase I/IIa study is evaluating the safety, immunogenicity of
combined two investigational therapeutic vaccines (an adenovirus serotype 26 vector vaccine (Ad26) and an MVA vector vaccine (MVA)) with a [Gilead] TLR7 agonist (an investigational drug that works on a protein of the immune system) into a treatment regimen to be administered alongside ART". http://natap.org/2016/HIV/110916_03.htm
AGING POPULATION with HIV - My reporting often includes comments about Aging & HIV. 80% of HIV+ now are over 45 years old - 50% over 50 - and 20% over 60 as reported by the DOHs in SF, NY, Boston, and Florida http://www.natap.org/2017/HIV/012717_03.htm- and older aging patients often struggle with daily activities of living due to disability, lack of mobility, multi-comorbidity & polypharmacy, cognitive impairment, falls & fractures, CVD, yet what is lacking, what is needed is a National Discussion on Aging to include a program of special support services for patients and their clinics, education for clinicians led by the NIH, HHS leadership in HIV/AIDS.
Webcast: http://www.croiwebcasts.org/console/player/33575?mediaType=slideVideo&